ロード中...
Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence
The biologic antitumor necrosis factor alpha (anti-TNFα) agents have revolutionised the treatment of inflammatory bowel disease (IBD). However, some patients experience primary nonresponse, loss of response, or intolerance. Therefore, introducing a newer class of therapy with a mechanism of action t...
保存先:
| 出版年: | World J Gastroenterol |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Baishideng Publishing Group Inc
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6010939/ https://ncbi.nlm.nih.gov/pubmed/29930467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v24.i23.2457 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|